Biomaterials Forum

The current issue of SFB Quarterly is only available to Members. Click here to login or join.

About Biomaterials Forum

Biomaterials Forum serves the biomaterials community and is the official news magazine of the Society For Biomaterials. It is published quarterly by the Society For Biomaterials and is sent to all Society members as a benefit of membership. Non-members may subscribe to the magazine for $48 per year. Direct any membership inquiries to the Membership Department at the Society office (e-mail to

It is the policy of the Society For Biomaterials that all articles reflect only the views of the authors and that publication of articles or advertisements within the Biomaterials Forum does not constitute endorsement  by the Society For Biomaterials or its agents of products, services, or views expressed. No representation is made as to the accuracy hereof and the publication is printed subject to errors and omissions. Articles that do not have an author byline may originate from press releases.

Editorial contributions to Biomaterials Forum are always welcome. Contributions should be sent to the Managing Editor. Authors should refer to the Author Guidelines when writing submissions. The publisher accepts no responsibility for the return or safety of artwork, photographs, or manuscripts. Receipt of editorial contributions does not imply or guarantee acceptance.

Click here for Biomaterials Forum advertising information.

Address corrections should be directed to Biomaterials Forum, Attn: Pam Gleason 1120 Route 73, Suite 200, Mt. Laurel, NJ 08054. (Subscribers, please include label.)

Requests for advertisement space should be directed to Amy Chezem at Advertisements are subject to General Conditions of Sale.

Unauthorized reproduction of Biomaterials Forum in whole or in part is prohibited. Requests for permission should be directed to the Managing Editor.

Scientific photos may be submitted for cover consideration in future issues. Submit color photo, credit information, and scientific description to the Executive Editor.

Click here for complete list of Editorial Board and SIG Reporters.

Media Kit


SFB News

Dr. Cato T. Laurencin, CEO of The Connecticut Convergence Institute for Translation in Regenerative Engineering at UConn Health, has created a new classification system for cell-based therapies.